A personalized therapeutic approach for cancer containing the African-centric P47S variant of TP53

We previously performed a drug screen in WT and P47S HepG2, and we found that Lexibulin (an anti-mitotic compound) preferentially decreases cell viability in the P47S mutant compared to WT. Our preliminary data show that Lexibulin induces p53 target gene expression but no apparent differences in cell death between WT and P47S HepG2.

We performed RNA-seq to capture the whole transcriptional profile, comparing our vehicle controls to Lexibulin-treated cells, and comparing Lexibulin-treated WT to Lexibulin-treated P47S cells to identify key genes that contribute to preferential targeting of P47S HepG2 in an unbiased manner.